Fabian Gerlinghaus

The future of CAR T-cell therapies will continue to improve as they expand to other patients in need.

Delivering the same safe product to a patient while improving timelines of clinical trials

Obtaining the right patient population for a CAR T-cell clinical trial is based off several factors from both the patient and the site.

Effective strategies for fostering strong communication and teamwork with a clinical trial site.

How the right site can set up for a successful clinical trial for CAR T-cell therapy.

Transferring knowledge and continuing to work together with regulatory agencies will lead to changes in approval going forward.

Examining hurdles surrounding FDA approval and how to streamline the process

Proper planning can assist in the institutional biosafety committee (IBC) review process when preparing for CAR T-cell clinical trials.

Understanding how pharmaceutical companies can navigate regulatory oversight through streamlined techniques and logistical planning.

Panelists set up for addressing the clinical trial landscape, key challenges, regulations, and the future of cell and gene therapy.